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Abstract
Background: DNA methylation, histone modifications and nucleosome occupancy act in concert for regulation of
gene expression patterns in mammalian cells. Recently, G9a, a H3K9 methyltransferase, has been shown to play a
role in establishment of DNA methylation at embryonic gene targets in ES cells through recruitment of de novo
DNMT3A/3B enzymes. However, whether G9a plays a similar role in maintenance of DNA methylation in somatic
cells is still unclear.
Results: Here we show that G9a is not essential for maintenance of DNA methylation in somatic cells. Knockdown
of G9a has no measurable effect on DNA methylation levels at G9a-target loci. DNMT3A/3B remain stably anchored
to nucleosomes containing methylated DNA even in the absence of G9a, ensuring faithful propagation of
methylated states in cooperation with DNMT1 through somatic divisions. Moreover, G9a also associates with
nucleosomes in a DNMT3A/3B and DNA methylation-independent manner. However, G9a knockdown synergizes
with pharmacologic inhibition of DNMTs resulting in increased hypomethylation and inhibition of cell proliferation.
Conclusions: Taken together, these data suggest that G9a is not involved in maintenance of DNA methylation in
somatic cells but might play a role in re-initiation of de novo methylation after treatment with hypomethylating
drugs, thus serving as a potential target for combinatorial treatments strategies involving DNMTs inhibitors.
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Background
DNA methylation is an essential epigenetic gene silen-
cing mechanism which interplays with histone modifica-
tions and nucleosome occupancy for regulation of
t i s s u e - s p e c i f i cg e n ee x p r e s s ion patterns and chromatin
architecture in mammalian cells [1]. DNA methylation
patterns are established during embryogenesis and then
faithfully maintained in differentiated tissues, enabling
preservation of cellular identity through multiple
somatic divisions. Failure in proper maintenance of
methylation patterns can result in development of dis-
ease states such as cancer [2,3]. Thus, it is essential to
faithfully maintain DNA methylation patterns in differ-
entiated cells through somatic divisions.
In mammals, the de novo DNA methytransferases,
DNMT3A/3B, primarily establish the methylation
patterns during embryonic development [4] and later
maintain them in differentiated tissues through coop-
eration with the maintenenace DNA methyltransfer-
ase, DNMT1 [5-7]. Recent studies by our group and
others have revealed distinct maintenance mechan-
isms used by these enzymes for preservation of
methylation patterns in somatic cells [8,9]. While
DNMT1 transiently interacts with the chromatin and
primarily performs its maintenance activity in
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remain preferentially bound to nucleosomes in chro-
matin regions containing methylated repeats and
CpG islands, which stabilizes these proteins and
assists in faithful propagation of DNA methylation
within the methylated domains through cooperative
activity of DNMT3A/3B and DNMT1 enzymes [9-11].
However, the mechanisms responsible for preferential
targeting of DNMT3A/3B to such methylated regions
are still poorly understood.
In embryonic stem (ES) cells, targeting of de novo
DNMT3A/3B enzymes to specific chromatin regions
involves interactions with auxiliary factors in addition to
their direct interactions with the nucleosomes [12,13].
DNMT3A/3B interact with various chromatin-associated
proteins including heterochromatin protein 1 (HP1), his-
tone deacetylase 1 (HDAC1), UHRF1 and histone
methyltransferases such as EZH2, suggested to play a
role in recruitment of DNMT3A/3B to specific chroma-
tin regions for de novo methylation in ES cells [9,13,14].
However, recent studies suggest that these auxiliary pro-
teins are not required for interaction of DNMT3A/3B
with the nucleosomes in somatic cells suggesting exis-
tence of other mechanisms involved in association of
DNMT3A/3B with chromatin [10].
H3K9 methylation has also been established to inter-
play with DNA methylation for gene silencing in cells.
In neurospora crassa,H 3 K 9m e t h y l a t i o nd i r e c t sD N A
methylation to transposable elements [15,16]. A similar
link between H3K9 methylation and DNA methylation
is present in mammals where heterochromatic H3K9
methyltransferase, Suv39h1, has been shown to direct
DNA methylation to major satellite repeats at peri-
centric heterochromatin [17]. Recently, G9a, a euchro-
matic H3K9 methyltransferase, has also been found to
direct DNA methylation to H3K9 methylated regions
in ES cells [18]. G9a, along with its partner protein
GLP, is crucial for H3K9 (mainly H3K9me and
H3K9me2) methylation of euchromatin and is involved
in transcriptional silencing [19,20]. G9a binds to its
own product, H3K9me and H3K9me2 residues,
through its ankyrin domain, a mechanism suggested to
play a role in propagation of H3K9 methylation
through cell divisions [21,22]. Recent studies have
shown that G9a physically interacts with Dnmt3a/3b
and recruits them to G9a-target gene promoters, retro-
transposons and major satellite repeats for de novo
methylation in ES cells [23], independent of its histone
methyltransferase activity [24]. While an essential role
of G9a in directing de novo DNA methylation in ES
cells has been established, whether it plays a similar
role in maintenance of DNA methylation patterns in
somatic cells remains unclear.
Here we show that G9a is not required for anchoring
of DNMT3A/3B to nucleosomes in methylated chroma-
tin regions and for maintenance of DNA methylation in
somatic cells. Using sucrose gradient chromatin fractio-
nation analysis, we show that G9a strongly binds to
both mononucleosomes and polynucleosomes, similar to
DNMT3A/3B. However, knockdown of G9a in somatic
cells does not decrease binding of DNMT3A/3B to
nucleosomes and no discernible reduction in DNA
methylation levels of G9a-associated target genomic
regions occurs even in the absence of G9a, suggesting
no role of G9a in maintenance of DNA methylation.
However, G9a-knockdown renders cancer cells more
sensitive to 5-Aza-CdR (5-aza-2’-deoxycytidine) treat-
ment resulting in increased DNA hypomethylation and
cell growth inhibition, indicating that G9a might be
involved in re-initiation of de novo methylation and thus
could serve as a promising target for combinatorial can-
cer treatment strategies involving DNA hypomethylating
drugs.
Results
G9a strongly associates with polynucleosomes similar to
DNMT3A/3B
To test the role of G9a, the euchromatic histone
methyltransferase, in the strong nucleosome anchoring
manifested by DNMT3A/3B, we examined their
nucleosomal binding patterns using sucrose density
gradient analysis. We subjected purified HCT116
nuclei to partial digestion with MNase, which cuts lin-
ker DNA to generate nucleosomal fragments of various
sizes, yielding a mixture of mono- and poly-nucleo-
somes. The nucleosomal digests were then fractionated
on sucrose gradients containing 300 mM NaCl and the
distribution of chromatin-associated proteins analyzed
through immunoblotting (Figure 1A). G9a associated
strongly with polynucleosomes with substantial
amounts of G9a protein sedimenting in nucleosome-
containing fractions, possibly in association with its
own enzymatic products, H3K9me and H3K9me2 [21].
Strikingly, the sedimentation profile of G9a was very
similar to that of DNMT3A/3B (Figure 1B). Interest-
ingly, SUV39h1, the heterochromatic histone methyl-
transferase, was also found associated with the
polynucleosomes. However, its sedimentation profile
was slightly shifted towards the bottom fractions of the
gradient, containing the larger chromatin fragments
indicating association with the condensed heterochro-
matin [17,25,26] (Figure 1A, B). Strong association of
DNMT3A/3B and histone methyltransferases with
nucleosomes is in agreement with the inheritance
model recently proposed for DNA methylation and
histone modifications where the enzymes remain
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propagation [8,21,26,27].
G9a tightly binds to intact mononucleosomes
We next asked whether G9a could bind to mononucleo-
somes in a manner similar to that previously observed
for DNMT3A/3B. Mononucleosomal MNase digests
from HCT116 cells were analyzed on sucrose gradients
containing 300 mM NaCl. Mononucleosomes containing
approximately 146 bp DNA fragments and core histones
localized in a peak at fraction 6 (Figure 2A). DNMT1
dissociated from nucleosomes, forming a peak at frac-
tion 4, while DNMT3A/3B formed a peak at fraction 7
suggesting that DNMT3A/3B are bound to mononu-
cleosomes and that their presence altered the sedimen-
tation of bound nucleosomes by one fraction relative to
Figure 1 Strong association of G9a and SUV39h1 with polynucleosomes similar to DNMT3A/3B. (A) Nucleosomes released from nuclei
partially digested with MNase at low ionic strength were resolved by ultracentrifugation on a sucrose density gradient (5% to 25%) containing
300 mM NaCl. Gradients were fractionated and analyzed as described in the Methods section. Ponceau S staining shows core histones
transferred onto the membrane from the SDS/PAGE gel. The control lanes (denoted as C) on the gels were loaded with unfractionated nuclear
extract loaded on the gels to monitor the quality of the immunostaining of the membranes. (B) Quantitation of protein bands obtained from
the western blot was done using Quantity One software (Bio-Rad). Plotting of levels of individual proteins in each fraction shows co-
sedimentation of G9a and DNMT3A/3B while SUV39h1 shows a sedimentation profile shifted towards bottom of the gradient indicating
association with heavier condensed heterochromatin fragments.
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anchored to the mononucleosomes similar to
DNMT3A/3B enzymes. SUV39h1 also displayed strong
binding to mononucleosomes (Additional file 1, Figure
S1). However, under such extensive digestion of chro-
matin, a substantial portion of cellular SUV39h1 protein
dissociated from the nucleosomes, possibly due to dis-
ruption of condensed heterochromatin structure [25].
The sedimentation profiles of G9a and SUV39h1
showed marked changes when the extent of MNase
digestion was altered from partial to extensive (Figure 1,
2A, S1), similar to that observed previously for
DNMT3A/3B [10], indicating physical association of
these proteins with nucleosomes. Similar binding of G9a
and SUV39h1 to mononucleosomes was also observed
in 293T cells indicating that the strong nucleosomal
association of these proteins takes place in both cell
types and is not due to potential cell type-specific inter-
actions (Additional file 1, Figure S1).
To further explore whether these enzymes require
intact nucleosomal structures for their association with
chromatin, we performed the sucrose gradient analysis
on the mononucleosomes treated with ethidium bro-
mide (EtBr) which disrupts the nucleosomal structure
by intercalating into DNA but does not interfere with
the protein-protein interactions [17,28-30]. Mononu-
cleosomes were incubated with EtBr prior to loading
onto sucrose gradients containing 300 mM NaCl (Figure
Figure 2 G9a along with DNMT3A/3B binds to intact nucleosomal structures. Mononucleosomes released by extensive digestion with
MNase were incubated in the absence (A) or presence (B) of 300 μg/ml EtBr for 10 min at room temperature, before loading onto the sucrose
density gradients (5% to 25%) containing 300 mM NaCl. In (A), absorbance of each fraction, read at 260 nm, has been plotted on the top to
represent the amount of DNA sedimenting in each fraction. Gradients were fractionated and analyzed as described previously.
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lar to DNMT3A/3B, upon disruption of nucleosomal
structure by EtBr with the enzymes now sedimenting
mainly in factions 3 to 5, which do not contain mea-
sureable histone components of the nucleosome. These
data show that G9a and DNMT3A/3B enzymes require
intact nucleosomal structures for their association with
chromatin.
G9a is not essential for maintenance of DNA methylation
in somatic cells
Recently, G9a was shown to direct DNA methylation to
retrotransposons, major satellite repeats and densely
methylated CpG-rich promoters in ES cells through
recruitment of DNMT3A/3B proteins [23]. To ascertain
whether a similar role of G9a exists in maintenance of
DNA methylation in somatic cells, we knocked down
G9a in HCT116 cells using shRNA constructs. G9a pro-
tein levels were severely reduced in G9a shRNA
(shG9a5, shG9a7) infected cells compared to the non-
specific shRNA (NS) control infected cells (Figure 3A).
DNMT3A protein levels did not show any difference
among the infected cell lines. Next we examined DNA
methylation levels at various CpG poor and CpG island
promoter regions and repeats in G9a knockdown (G9a-
kd) and control infected HCT116 cells. We selected six
highly methylated regions including some previously
verified G9a-target regions in HCT116 cells [31] (CpG
poor promoters: RUNX3P1, MAGE-A1, SPANXA1;C p G
island promoters: ATBF1, XAGE1; Repeats: LINE1)a n d
one unmethylated region (CpG island: RUNX3P2)f o r
our analysis [18-20,23,32]. Cooperative activity of
DNMT3A/3B and DNMT1 has been previously shown
to be required for maintenance of DNA methylation at
these methylated loci in HCT116 cells [33-35]. We did
not observe any substantial change in DNA methylation
levels at the analyzed regions in the G9a-kd cells com-
pared to control infected HCT116 cells (Figure 3B).
These data suggest that unlike in ES cells, G9a is not
essential for maintenance of DNA methylation at these
loci in somatic cells, in agreement with some other
recent studies [31,36].
DNMT3A/3B do not require G9a for anchoring to
nucleosomes
The finding that DNA methylation is maintained in the
absence of G9a in somatic cells prompted us to examine
whether DNMT3A/3B, which are recruited and
anchored to target chromatin regions by G9a for DNA
methylation in ES cells [23,24], can still strongly associ-
ate with nucleosomes even in the absence of G9a in
somatic cells. Since DNMT3A/3B cooperate with
DNMT1 for maintenance of DNA methylation at var-
ious methylated genomic loci in somatic HCT116 cells,
including the G9a-target loci examined in this study
[33], their continued association with such loci might
enable faithful propagation of DNA methylation even in
the absence of G9a. We analyzed mononucleosomal
digests from HCT116 cells infected with either G9a
shRNA or non-specific control on sucrose gradients
containing 300 mM NaCl. DNMT3A/3B along with G9a
were tightly associated with nucleosomes in the control
cells as expected (Figure 4A). Interestingly, even in G9a
knockdown cells, DNMT3A/3B remained strongly
bound to the nucleosomes indicating their continued
association with the target loci even in the absence of
G9a. Taken together, these data indicate that in somatic
cells, the strong association of DNMT3A/3B with
methylated chromatin regions is not mediated by G9a
and DNMT3A/3B, in cooperation with DNMT1, can
faithfully maintain DNA methylation at their target loci
independent of G9a. We also asked whether impaired
DNA methylation could feed back on H3K9 methyla-
tion, as previously suggested [37], and disrupt binding of
G9a to H3K9 methylated regions. Mononucleosomal
digests from severely hypomethylated DNMT-deficient
DKO1 (DNMT1
ΔE2-5, DNMT3B
-/- ) cells, containing
severely reduced levels of DNMT3A [11,33], were
Figure 3 Depletion of G9a does not impair maintenance of
DNA methylation in somatic cells. (A) Western blot of nuclear
extracts from HCT116 cells infected with either control (NS) shRNA
or shRNAs against G9a (shG9a5 or shG9a7), prepared 14 days after
infection. (B) The levels of DNA methylation at different loci in
HCT116 cells infected with either control (NS) shRNA or shRNAs
against G9a (shG9a5 or shG9a7) were measured through Ms-SNuPE
14 days after infection. Data represent mean and SEM of
methylation levels measured at three independent CpG sites within
each locus.
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NaCl. The majority of G9a was found tightly anchored
to nucleosomes even in DKO1 cells indicating that a
loss of DNA methylation and absence of DNMTs does
not affect G9a’s association with the chromatin which
is in agreement with a previous study [18] (Figure 4B).
Interestingly, we did observe a slight shift towards the
top of the gradient in sedimentation profiles of
DNMT3A/3B in G9a-kd cells and G9a in DNMT-defi-
cient DKO1 cells, with the proteins sedimenting a frac-
tion higher on the gradient which might result from
the absence of respective chromatin-associated pro-
teins in these cells. We have previously shown that
binding of chromatin-associated enzymes like
DNMT3A/3B with mononucleosomes alters the sedi-
mentation of bound nucleosomes by one fraction rela-
tive to bulk mononucleosomes towards the bottom of
the gradient (DNMT3A/3B form a peak in fraction 7
compared to peak of core histones in fraction 6 (Figure
2 A ) )d u et oa ni n c r e a s ei nm o l e c u l a rw e i g h to ft h e
enzymes-bound nucleosomes [10]. Thus while in
HCT116 N/S cells, mononucleosomes bound to G9a
and DNMT3A/3B (possibly bound as part of a com-
mon protein complex) form a peak in fraction 7 of the
gradient, absence of either of these nucleosome-bind-
ing proteins in HCT116 G9a-kd cells and DNMT-defi-
cient DKO1 cells results in a decrease in molecular
weight of such enzyme-bound nucleosomes and hence
a shift in their sedimentation profile towards the top
of the gradient forming a peak in fraction 6. However,
our gradient data clearly suggests that while G9a and
DNMT3A/3B might bind to nucleosomes in similar
chromatin regions, their nucleosome binding is inde-
pendent of presence of each other.
Figure 4 DNMT3A/3B and G9a do not require each other for anchoring to nucleosomes in somatic cells. Mononucleosomal digests
prepared by extensive MNase digestion of nuclei from (A) HCT116 cells infected with either control NS shRNA or shG9a5 shRNA as shown in
Figure 3 and (B) hypomethylated DKO1 cells, were resolved by ultracentrifugation on a sucrose density gradient (5% to 25%) containing 300
mM NaCl. Gradients were fractionated and analyzed as described previously. Western blot was highly overexposed for detecting residual G9a
protein in the shG9a5 shRNA infected HCT116 cells. * Overexposed.
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cated ΔDNMT3B variants, which lack parts of N-term-
inal domain of DNMT3B including the PWWP domain
but possess a conserved active catalytic domain, to
nucleosomes (Figure 5A). The truncated ΔDNMT3B
variants have been associated with aberrant promoter
methylation in non-small cell lung cancer (NSCLC) cell
lines, possibly arising from their aberrant targeting due
to a reduction in their chromatin binding affinities
[10,38,39]. G9a associates with DNMT3A/3B through
the interaction of its ankyrin domain with the catalytic
domains of DNMT3A/3B [23], therefore it should be
able to physically interact and recruit catalytically active
ΔDNMT3B variants to the target chromatin regions.
Mononucleosomal digests from 293T cells expressing
Myc-tagged ΔDNMT3B variants were analyzed on
sucrose gradients containing 300 mM salt. While G9a
remained tightly bound to the nucleosomes, the delta
DNMT3B variants completely dissociated from the
nucleosomes (Figure 5B). Taken together, these data
suggest that unlike in ES cells, where G9a is essential
for DNA methylation through recruitment of
DNMT3A/3B enzymes to the H3K9 methylated chro-
matin regions, G9a is not essential for anchoring of
DNMT3A/3B to the nucleosomes and for propagation
of DNA methylation in somatic cells.
Figure 5 G9a cannot anchor ΔDNMT3B truncated variants to the nucleosomes. (A) Map of DNMT3B1 and Delta DNMT3B isoforms showing
the PWWP and PHD-like domains located in the N-terminal regions, and the catalytic methylase domains in the C-terminal region. (B)
Mononucleosomal digests prepared by extensive MNase digestion of nuclei from 293T cells expressing either ΔDNMT3B2 or ΔDNMT3B4, were
resolved by ultracentrifugation on a sucrose density gradient (5% to 25%) containing 300 mM NaCl. Gradients were fractionated and analyzed
through immunoblotting as described previously.
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resulting in increased DNA hypomethylation and
inhibition of cell growth
While our results suggested no role of G9a in maintain-
ing DNA methylation in somatic cells, it remained plau-
sible that G9a might be involved in re-initiation of de
novo DNA methylation (rebound methylation) at hypo-
methylated sites after treatment with hypomethylating
drugs, a phenomenon commonly observed after treat-
ment of cancer cells with DNA methylation inhibitors
[33]. Since G9a plays a role in directing de novo DNA
methylation to various G9a target regions in ES cells
[23], a similar role of G9a in directing rebound methyla-
tion in somatic cells is possible. Therefore, we hypothe-
s i z e dt h a tk n o c k d o w no fG 9 am i g h ts y n e r g i z ew i t h
treatment with DNMTs inhibitors enabling greater
reduction in DNA methylation through inhibition of
interplay between the histone methylation and DNA
methylation machineries. To test this hypothesis, we
treated G9a shRNA (shG9a5) and non-specific control
(NS) infected HCT116 cells with 5-Aza-CdR (5-aza-2’-
deoxycytidine). Strikingly, G9a-kd cells treated with 5-
Aza-CdR showed substantially greater inhibition of cell
proliferation compared to 5-Aza-CdR treated control
infected HCT116 cells (Figure 6A). Analysis of DNA
methylation at the MAGE-A1 promoter, a G9a-target
locus, and p16exon2, 72 hrs after drug treatment showed
greater reduction in DNA methylation at both loci in
G9a-kd cells compared to control infected cells (Figure
6B). The increased hypomethylation of MAGE-A1 locus
in 5-Aza-CdR treated G9a-kd cells compared to non-
specific control treated cells was further confirmed by
bisulfite sequencing showing a decrease in MAGE-A1
promoter methylation to 45% in G9a-kd cells compared
to 55% in NS control cells after drug treatment (Addi-
tional file 2, Figure S2). Since both G9a-kd and control
HCT116 cells displayed similar growth rates in mock
PBS treatments, the increased hypomethylation caused
by 5-Aza-CdR in G9a-kd cells compared to control cells
was not due to differential incorporation of the drug
into replicating DNA in these cells (Figure 6A). How-
ever, while we did see reduced methylation levels 72 hrs
after 5-Aza-CdR treatment, DNA methylation levels
recovered to their initial high levels in both G9a-kd and
control HCT116 cells with increased time in culture
(Day 15), possibly due to the activity of residual
DNMT3A/3B enzymes still associated with such regions
and the gradual recovery in levels of cellular DNMT3A/
3B and DNMT1 enzymes in absence of the hypomethy-
lating drug [11,40]. After observing the pronounced
inhibition of cell proliferation by 5-Aza-CdR upon
depletion of G9a, we also tried pharmacologic inhibition
of G9a by performing a double treatment using a G9a-
inhibitor, BIX-01294 [41] in combination with 5-Aza-
CdR. However, BIX-01294 was very toxic to cells, as
previously discussed [42], and thus could not be used
for combination treatment. Taken together, these data
suggest that G9a knockdown synergizes with DNMTs
inhibition leading to higher cell growth inhibition and
DNA hypomethylation and G9a might serve as an effec-
tive target for combinatorial cancer treatment strategies
involving DNMTs inhibitors.
Discussion
We have previously shown that the majority of
DNMT3A/3B strongly anchor to nucleosomes contain-
ing methylated DNA in somatic cells. Such binding,
which requires the presence of DNA methylation,
further stabilizes these proteins [10,11]. Based on these
data, we proposed a revised inheritance model for DNA
methylation where DNMT3A/3B remain associated with
methylated chromatin domains i.e. in association with
their product 5-methylcytosine enabling proper mainte-
nance of DNA methylated states through somatic divi-
sions in cooperation with DNMT1 [8]. This model is
similar to proposed inheritance models for histone
marks where the histone methyltransferases remain
Figure 6 Increased DNA hypomethylation and growth
inhibition by 5-Aza-CdR in G9a knockdown cells. (A) Cell
growth curve and (B) DNA methylation levels at MAGE-A1 and
p16exon2 locus, of G9a-knockdown (shG9a5) and control (NS)
HCT116 cells treated with either PBS or 5-Aza-CdR. Cells were
treated with the drug for 24 h. The drug containing media was
then replaced with fresh media. The cells were kept in culture and
cell counts and DNA methylation levels were assessed at respective
time points. For 5-Aza-CdR treatment, samples examined were taken
after 3 (Day 3) and 15 (Day 15) days of drug treatment. For PBS
control treatment, sample examined was taken after 3 days of drug
treatment. DNA methylation levels were measured using Ms-SNuPE
assay as described in the Methods section. Data represent mean
and range of methylation levels from two independent biological
replicate drug treatment experiments, in each measuring
methylation levels at three independent CpG sites within each
locus.
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own mark enabling faithful maintenance [21,26,27]. The
strong binding of DNMT3A/3B and H3K9 methyltrans-
ferases, G9a and SUV39h1, to nucleosomes observed in
our sucrose density gradient experiments strongly sup-
ports the existence of such proposed inheritance models.
Whether a common link exists between these two simi-
lar inheritance models for H3K9 methylation and DNA
methylation is still unclear. H3K9 methylation and DNA
methylation patterns are found to be highly coincident
in mammalian cells [14,43,44] suggesting the possibility
of interplay between these two epigenetic machineries.
Indeed recent studies revealed such a link between these
two mechanisms in ES cells where G9a was shown to
direct DNA methylation to certain loci in ES cells [9].
However, the presence of a similar role of G9a in direct-
ing maintenance of DNA methylation in somatic cells is
still inconclusive.
Here we have shown that unlike in ES cells, G9a is
not essential for propagation of DNA methylation in
somatic cells since depletion of G9a in somatic cells
did not impair maintenance of DNA methylation at
G9a-target loci. Our data are in agreement with some
other recent studies indicating that while G9a is essen-
tial for de novo methylation, it is dispensable for main-
tenance of DNA methylation [31,36]. In addition, our
data provide insights into possible mechanisms respon-
sible for such G9a-independent maintenance of DNA
methylation in somatic cells. We have shown that
DNMT3A/3B remain bound to methylated chromatin
r e g i o n se v e ni nt h ea b s e n c eo fG 9 ai n d i c a t i n gt h a t
these enzymes do not require G9a for their presence at
silent methylated domains and they can faithfully
maintain DNA methylation in somatic cells indepen-
dent of G9a.
Based on previous studies in ES cells and our current
data, we propose that G9a primarily plays a role in
establishment of DNA methylation at target loci in ES
cells by recruiting DNMT3A/3B for de novo methyla-
tion at such regions. G9a may act in concert with
DNMT3L, a regulatory factor expressed only in ES
cells which stimulates DNMT3A/3B activities [45], in
the de novo methylation process. However, once the
methylation patterns have been established, DNMT3A/
3B remain stably associated with nucleosomes in
methylated chromatin regions in somatic cells, inde-
pendent of G9a, and faithfully propagate DNA methy-
lation in such domains in cooperation with DNMT1
through multiple somatic divisions. One possible rea-
son for such differential effects of G9a on DNA methy-
lation observed in ES cells compared to somatic cells
might be the greater level of ‘epigenetic plasticity’ in
the ES cells. ES cells require a plastic epigenome since
they need to reprogram themselves along specific
lineages [46]. In contrast, differentiated somatic cells
possess a more restricted chromatin structure which
they need to faithfully maintain to preserve their cellu-
lar identity through somatic divisions [46]. Therefore,
in somatic cells, DNMT3A/3B enzymes remain stably
associated with the previously methylated chromatin
domains ensuring faithful maintenance of methylated
states without causing any aberrant de novo methyla-
tion [11]. Interestingly, we also found that the pre-
sence/absence of DNA methylation does not affect
association of G9a, which binds to H3K9me and
H3K9me2 residues, with nucleosomes. While
DNMT3A/3B require DNA methylation for their bind-
ing to nucleosomes [11], our current data suggest that
impaired DNA methylation does not affect G9a’s asso-
ciation with H3K9 methylated chromatin regions and
distinct mechanisms are involved in localization of
these enzymes in somatic cells.
Our data also show that while G9a is not required
for maintenance of DNA methylation in differentiated
cells, simultaneous targeting of G9a and DNMTs
results in increased inhibition of cell proliferation and
greater DNA hypomethylation. The striking increase in
inhibition of cell proliferation observed in our experi-
ments highlights the strong potential of combinatorial
cancer treatment strategies targeting repressive histone
methylation and DNA methylation machineries
together. The pronounced cell growth inhibition
observed upon simultaneous knockdown of G9a along
with treatment with 5-Aza-CdR might be a result of
widespread changes in DNA methylation and accom-
panying changes in histone modifications [47]. Our
data also show that such combinatorial targeting
approach further increases the efficacy of the DNA
hypomethylating drugs in reducing levels of DNA
methylation. The increase in DNA hypomethylation
might arise from a possible role of G9a in re-initiating
DNA methylation at hypomethylated sites after 5-Aza-
CdR treatment. G9a might direct DNA methylation at
such hypomethylated sites through recruitment of de
novo DNMT3A/3B enzymes, similar to its role in ES
cells [23]. Inhibition of G9a protein observed during 5-
Aza-CdR treatment further supports a role of simulta-
neous inhibition of DNMTs and G9a in drug-induced
DNA hypomethylation [48]. It is also possible that the
increased DNA hypomethylation observed upon 5-Aza-
CdR treatment of G9a knockdown cells might have
arisen from an alteration in the cell growth rate lead-
ing to differential drug incorporation in DNA. 5-Aza-
CdR has been previously shown to result in severe
hypomethylation of rapidly dividing cells [49]. How-
ever, 5-Aza-CdR treated G9a-kd cells displayed a
reduced growth rate compared to treated G9a WT
cells ruling out such a possibility.
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Taken together, our data suggest that G9a is not
required for preferential targeting of DNMT3A/3B to
silent methylated domains and faithful maintenance of
DNA methylation in differentiated somatic cells. How-
ever, G9a might serve as a potential target for combina-
torial cancer treatment strategies involving DNMTs
inhibitors to achieve greater drug-induced DNA hypo-
methylation and anti-proliferation effects.
Methods
Cell culture
HCT116 and 293T cells were maintained in McCoy’s5 A
and DMEM, respectively, containing 10% inactivated
fetal bovine serum, 100 units/ml penicillin, and 100 μg/
ml streptomycin. Puromycin was included in the culture
medium at 3 μg/ml to maintain infected cells. 293T
cells expressing different ΔDNMT3B isoforms were pre-
pared as described previously [10]. For 5-Aza-CdR treat-
ment experiments, cells were cultured in the presence of
0.3 μM 5-Aza-CdR for 24 h. After 24 h, the drug con-
taining media was replaced with fresh media and cells
were kept in culture till the mentioned time points. Cell
counts were made using Coulter Counter (Beckman
Coulter, Brea, CA).
Nuclei preparation
Nuclei were prepared according to the procedure
described previously [50]. Briefly, cells were trypsinized
and washed once with PBS. The cells were then resus-
pended in ice-cold RSB buffer (10 mM Tris-HCl, pH
7.4, 10 mM NaCl, 3 mM MgCl2) containing protease
inhibitors and kept on ice for 10 min before Dounce
homogenization in the presence of 0.5% to 1% NP-40 to
break up cell membranes. Nuclei were washed twice
with RSB plus the protease inhibitors (Roche) without
the detergent. Nuclear extracts were prepared by resus-
pending nuclei in RIPA buffer (50 mM Tris-HCl, pH
8.0, 150 mM NaCl, 1% NP-40, 0.5% DOC, 0.1% SDS)
followed by sonication.
MNase digestion and sucrose density gradient
centrifugation
Sucrose density gradient experiments were performed as
described previously [10]. Purified nuclei (1x10
8)r e s u s -
pended in 1 ml of RSB containing 0.25 M sucrose, 3
mM CaCl2, and 100 μMP M S F ,w e r ed i g e s t e dw i t h3 6
units of MNase (Worthington) for partial and 500 units
of MNase (Worthington) for extensive digestion for 15
min at 37°C, and then the reaction was stopped with
EDTA/EGTA (up to 10 mM). After microcentrifugation
at 5,000 rpm for 5 min, the nuclear pellet was resus-
pended in 0.65 ml of the elution buffer (10 mM Tris-
HCl, pH 7.4, 10 mM NaCl) containing 5 mM EDTA/
EGTA, gently rocked for 1 hr at 4°C followed by micro-
centrifugation to obtain soluble nucleosomes. A quantity
of 0.55 ml of soluble nucleosome containing buffer was
fractionated through a sucrose density gradient solution
(5% to 25% sucrose, 10 mM Tris-HCl, pH 7.4, 0.25 mM
EDTA) containing NaCl of indicated concentrations, by
centrifuging at 30,000 rpm for 16 h at 4°C. Fractions
were taken from the top of the centrifuge tube to 16 ali-
quots. Proteins from same volume of each fraction (200
to 250 μl) were concentrated by TCA precipitation and
subjected to western blot analysis. The EtBr treatment
of the mononucleosome samples was done by adding 20
mg/ml EtBr to the samples (300 μg/ml at final), followed
by incubation at room temperature for 10 min before
loading onto the gradient.
Lentiviral knockdown
The lentivirus particles containing N/S, shG9a5 and
shG9a7 shRNA sequences were prepared using standard
protocols. For lentivirus production, the vesicular stoma-
titis virus envelope protein G expression construct pMD.
G1, the packaging vector pCMV ΔR8.91 and the transfer
vector pHRCMVpuroSin8 were used as described pre-
viously [51]. Short hairpin RNA sequences encoding
non-specific and sequences targeting G9a were as fol-
lows: N/S 5’- AAAACTGCAGAAAAAGGGTAGGT
TCGACTAGCAGGACTCTTCTCTTGAA
AGAGTCTTGCTAGTTGAACC-
TACCCGGTGTTTCGTCCTTTCCACAAG-3’;s h G 9 a 5
5’- AAAACTGCAGAAAAAGACAGCAAGTCTGAAGT
TGAAGCTCTCTCT
TGAAGAGCTTTAACTTCATACTTGCTGTCGGT
GTTTCGTCCTTTCCACAAG -3’ and shG9a7 5’-
AAAACTGCAGAAAAAGGATGAATCTGAGAATCT
TGAGGG
ATCTCTTGAATCCCTCCAGATTCTTAGATTCA
TCCGGTGTTTCGTCCTTTCCA
CAAG -3’. Infected HCT116 cells were selected in the
presence of 3 μg/ml puromycin for two weeks.
Western blot analysis
Proteins from the same volume of each fraction (200 to
250 μl) were concentrated by TCA precipitation, dis-
solved in SDS/b-mercaptoethanol loading buffer, and
resolved on a 4% to 15% gradient SDS/PAGE gel (Bio-
Rad, Hercules, CA). Antibodies against H3 (ab1791),
DNMT3A (ab2850), and SUV39h1 (ab12405) were pur-
chased from Abcam Inc. (Cambridge, UK); DNMT1 (sc-
20701) and DNMT3B (sc-10235) from Santa Cruz Bio-
tech (Santa Cruz, CA); Myc epitope tag (05-724) from
Upstate (now Millipore, Billerica, MA) and G9a (G
6919); b-Actin (A 5316) from Sigma (Saint Louis, MO).
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Page 10 of 12The image of individual proteins was visualized using
ECL detection system (Thermo Scientific, Waltham, MA
and Millipore, Billerica, MA).
DNA methylation analysis
Ms-SNuPE assay was performed as described previously
[52,53]. Genomic DNA was prepared from HCT116
cells infected with either N/S, shG9a5, or shG9a7 con-
structs 14 days after lentiviral infection. To analyze the
methylation status of individual DNA molecules, we
cloned bisulfite PCR fragments of the loci of interest
into the pCR2.1 vector using the TOPO-TA cloning kit
(Invitrogen, Carlsbad, CA). Primer sequences are avail-
able on request. Individual colonies were screened for
the insert and the region of interest was sequenced
using M13 primers. DNA methylation levels were esti-
mated by calculating the percentage of CpGs remaining
methylated from the total number of CpGs assayed
among all individual cells.
Additional material
Additional file 1: Figure S1. G9a and SUV39h1 strongly associate with
mononucleosomes in both HCT116 and 293T cells. Mononucleosomal
digests prepared by extensive MNase digestion of nuclei from (A)
HCT116 cells and (B) 293T cells were resolved by ultracentrifugation on a
sucrose density gradient (5% to 25%) containing 300 mM NaCl. Gradients
were fractionated and analyzed as described previously. The control
lanes (denoted as C) on the gels were loaded with unfractionated
nuclear extract loaded on the gels to monitor the quality of the
immunostaining of the membranes.
Additional file 2: Figure S2. Increased DNA hypomethylation of MAGE-
A1 promoter in G9a knockdown cells upon treatment with 5-Aza-CdR.
Methylation of MAGE-A1 promoter in G9a knockdown (shG9a5) and
control (NS) HCT116 cells, treated with 5-Aza-CdR and PBS, was analyzed
72 h after drug treatment using bisulfite sequencing. CpG sites in the
map of MAGE-A1 promoter are represented by the lower tick marks (top).
Each straight line, with circles representing CpG sites, represents MAGE-
A1 promoter sequence from a single cell (bottom). White circles indicate
unmethylated CpG sites and black circles indicate methylated CpG sites.
Cross indicates methylation status could not be determined. Residual
DNA methylation levels were estimated by calculating the percentage of
CpGs remaining methylated after drug treatment from the total number
of CpGs assayed for the MAGE-A1 loci among all individual cells.
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